Press Releases News Year None202020192018201720162015201420132012 IVERIC bio to Host a Zimura® R&D Symposium for Investors / Analysts on November 20, 2019 Nov 14, 2019 | IVERIC bio Reports Third Quarter 2019 Operational Highlights and Financial Results Nov 12, 2019 | IVERIC bio Initiating Second Pivotal Clinical Trial of Zimura® in GA with 1Q 2020 Targeted for First Patient Enrolled Nov 12, 2019 | IVERIC bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nov 05, 2019 | IVERIC bio to Report Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 12, 2019 Nov 04, 2019 | IVERIC bio Appoints Abraham Scaria, PhD, as Chief Scientific Officer Oct 29, 2019 | IVERIC bio’s Zimura®, a Novel Complement C5 Inhibitor, Met its Primary Endpoint and Reached Statistical Significance in a Phase 2b Randomized, Controlled Clinical Trial in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Oct 28, 2019 | CORRECTING and REPLACING IVERIC bio to Present at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference Sep 30, 2019 | IVERIC bio to Present at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference Sep 30, 2019 | IVERIC bio to Present at the Ladenburg Thalmann 2019 Healthcare Conference Sep 17, 2019 | Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
IVERIC bio to Host a Zimura® R&D Symposium for Investors / Analysts on November 20, 2019 Nov 14, 2019 |
IVERIC bio Initiating Second Pivotal Clinical Trial of Zimura® in GA with 1Q 2020 Targeted for First Patient Enrolled Nov 12, 2019 |
IVERIC bio to Report Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 12, 2019 Nov 04, 2019 |
IVERIC bio’s Zimura®, a Novel Complement C5 Inhibitor, Met its Primary Endpoint and Reached Statistical Significance in a Phase 2b Randomized, Controlled Clinical Trial in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Oct 28, 2019 |
CORRECTING and REPLACING IVERIC bio to Present at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference Sep 30, 2019 |
IVERIC bio to Present at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference Sep 30, 2019 |
Press Releases News Year None202020192018201720162015201420132012 IVERIC bio to Host a Zimura® R&D Symposium for Investors / Analysts on November 20, 2019 Nov 14, 2019 | IVERIC bio Reports Third Quarter 2019 Operational Highlights and Financial Results Nov 12, 2019 | IVERIC bio Initiating Second Pivotal Clinical Trial of Zimura® in GA with 1Q 2020 Targeted for First Patient Enrolled Nov 12, 2019 | IVERIC bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nov 05, 2019 | IVERIC bio to Report Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 12, 2019 Nov 04, 2019 | IVERIC bio Appoints Abraham Scaria, PhD, as Chief Scientific Officer Oct 29, 2019 | IVERIC bio’s Zimura®, a Novel Complement C5 Inhibitor, Met its Primary Endpoint and Reached Statistical Significance in a Phase 2b Randomized, Controlled Clinical Trial in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Oct 28, 2019 | CORRECTING and REPLACING IVERIC bio to Present at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference Sep 30, 2019 | IVERIC bio to Present at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference Sep 30, 2019 | IVERIC bio to Present at the Ladenburg Thalmann 2019 Healthcare Conference Sep 17, 2019 | Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
IVERIC bio to Host a Zimura® R&D Symposium for Investors / Analysts on November 20, 2019 Nov 14, 2019 |
IVERIC bio Initiating Second Pivotal Clinical Trial of Zimura® in GA with 1Q 2020 Targeted for First Patient Enrolled Nov 12, 2019 |
IVERIC bio to Report Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 12, 2019 Nov 04, 2019 |
IVERIC bio’s Zimura®, a Novel Complement C5 Inhibitor, Met its Primary Endpoint and Reached Statistical Significance in a Phase 2b Randomized, Controlled Clinical Trial in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Oct 28, 2019 |
CORRECTING and REPLACING IVERIC bio to Present at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference Sep 30, 2019 |
IVERIC bio to Present at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference Sep 30, 2019 |
